Bristol seeks another celmod use
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The company buys Belgium’s EsoBiotec for $425m.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.